France-based medtech company Defymed said today that it’s developing a novel insulin delivery device which it hopes to bring to market by the end of 2020. The company’s device, ExOlin, uses a biocompatible membrane that is nonbiodegradable and permeable to insulin, according to Defymed. The insulin delivery device is designed to be implanted into a patient’s abdomen […]
Defymed
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at MassDevice’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent […]
Defymed partners with Semma Therapeutics on bio-artificial pancreas
French biotech developer Defymed said today it inked a collaborative deal with American biotech company Semma Therapeutics to support the continued development of a bio-artificial pancreas to treat type-1 diabetes. The collaborative deal will aim to achieve pre-clinical validation of Defymed’s Mailpan bio-artificial pancreas in combination with Semma’s stem-cell derived differentiated insulin-secreting cells, Defymed said. The Mailpan device […]
JDRF backs Defymed for artificial pancreas study
French biotech developer Defymed said today that it is partnering with the Junior Diabetes Research Foundation to fund studies of the company’s Mailpan bioartifical pancreas. The Mailpan device is designed to be implanted in the abdomen, taking the shape of a pouch containing insulin-secreting cells to restore normal and continuous insulin production in diabetic patients. […]
